Savara (NASDAQ:SVRA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Savara (NASDAQ:SVRA) from a sell rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Savara Trading Up 1.4%

Shares of Savara stock opened at $5.07 on Friday. The firm has a market cap of $1.04 billion, a PE ratio of -8.74 and a beta of 0.25. Savara has a 1 year low of $3.34 and a 1 year high of $7.01. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The stock has a fifty day moving average price of $5.43 and a 200-day moving average price of $5.43.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Equities research analysts anticipate that Savara will post -0.61 EPS for the current year.

Institutional Trading of Savara

Several hedge funds have recently made changes to their positions in SVRA. Sequoia Financial Advisors LLC purchased a new position in shares of Savara during the 2nd quarter valued at $69,000. WINTON GROUP Ltd purchased a new stake in Savara in the 2nd quarter worth about $151,000. Arizona State Retirement System increased its holdings in Savara by 34.0% in the 2nd quarter. Arizona State Retirement System now owns 25,445 shares of the company’s stock worth $157,000 after acquiring an additional 6,456 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Savara in the 2nd quarter valued at about $194,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Savara by 120.5% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 116,222 shares of the company’s stock valued at $716,000 after acquiring an additional 63,504 shares during the period. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara’s lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs.